Intravenous iron therapy in end-stage renal disease

Seminars in Dialysis

Volumn 19, Issue 4, 2006, Pages 285-290

  Brewster, Ursula C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON DERIVATIVE;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; HUMAN; IMMUNOLOGY; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; REVIEW;

ANEMIA, IRON-DEFICIENCY; CARDIOVASCULAR DISEASES; HUMANS; INFECTION; INJECTIONS, INTRAVENOUS; IRON COMPOUNDS; KIDNEY FAILURE, CHRONIC;

EID: 33746237592     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2006.00174.x     Document Type: Review

References (58)

1. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36-39%. J Am Soc Nephrol 12:2465-2473, 2001
2. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11:530-538, 2000
3. Heath CW, Strauss MB, Castle WB: Quantitative aspects of iron deficiency in hypochromic anemia. J Clin Invest 11:1293-1312, 1932
4. Danielson BG: Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 15(suppl 2):S93-S98, 2004
5. Faich G, Strobos J: Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 33:464-470, 1999
6. Sunder-Plassmann G, Horl W: Comparative look at intravenous iron agents. pharmacology, efficacy, and safety of iron dextran, iron saccharate and ferric gluconate. Semin Dial 12:243-248, 1999
7. Fishbane S: Safety in iron management. Am J Kidney Dis 41:18-26, 2003
8. Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102:783-788, 2003
9. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. III. Iron support. Am J Kidney Dis 37:S194-S206, 2001
10. Boelaert JR, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ, Van Landuyt HW: Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant 5:130-134, 1990
11. Briggs WA, Pedersen MM, Mahajan SK, Sillix DH, Prasad AS, McDonald FD: Lymphocyte and granulocyte function in zinc-treated and zinc-deficient hemodialysis patients. Kidney Int 21:827-832, 1982
12. Besarab A: Parenteral iron therapy. safety and efficacy. Semin Dial 12:237-242, 1999
13. Collins A, Ebben J, Ma J: Frequent IV iron dosing is associated with higher infectious deaths [abstract]. J Am Soc Nephrol 9:190A, 1997
14. Hubel E, Kiefer T, Weber J, Mettang T, Kuhlmann U: In vivo effect of 1,25-dihydroxyvitamin D3 on phagocyte function in hemodialysis patients. Kidney Int 40:927-933, 1991
15. Vanholder R, Van Biesen W, Ringoir S: Contributing factors to the inhibition of phagocytosis in hemodialyzed patients. Kidney Int 44:208-214, 1993
16. van Asbeck BS, Marx JJ, Struyvenberg A, Verhoef J: Functional defects in phagocytic cells from patients with iron overload. J Infect 8:232-240, 1984
17. Patruta SI, Edlinger R, Sunder-Plassmann G, Horl WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9:655-663, 1998
18. Ellison RT 3rd, Giehl TJ: Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest 88:1080-1091, 1991
19. Bortner CA, Miller RD, Arnold RR: Bactericidal effect of lactoferrin on Legionella pneumophila. Infect Immun 51:373-377, 1986
20. Mencacci A, Cenci E, Boelaert JR, Bucci P, Mosci P, Fe d'Ostiani C, Bistoni F, Romani L: Iron overload alters innate and T helper cell responses to Candida albicans in mice. J Infect Dis 175:1467-1476, 1997
21. Collins HL: The role of iron in infections with intracellular bacteria. Immunol Lett 85:193-195, 2003
22. Collins HL, Kaufmann SH, Schaible UE: Iron chelation via deferroxamine exacerbates experimental salmonellosis via inhibition of the nicotinamide adenine dinucleotide phosphate oxidase-dependent respiratory burst. J Immunol 168:3458-3463, 2002
23. de Silva A, Atukorala S, Weerasinghe I, Ahluwalia N: Iron supplementation improves iron status and reduces morbidity in children with or without upper respiratory tract infections. Am J Clin Nutr 77:234-241, 2003
24. Williams P, Griffiths E: Bacterial transferrin receptors - structure, function and contribution to virulence. Med Microbiol Immunol (Berl) 181:301-322, 1992
25. Fishbane S: Review of issues relating to iron and infection. Am J Kidney Dis 34:S47-S52, 1999
26. Bullen JJ: The significance of iron in infection. Rev Infect Dis 3:1127-1138, 1981
27. Ward CG, Hammond JS, Bullen JJ: Effect of iron compounds on antibacterial function of human polymorphs and plasma. Infect Immun 51:723-730, 1986
28. Zanen AL, Adriaansen HJ, van Bommel EF, Posthuma R, de Jong GMT: "Oversaturation" of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients. Nephrol Dial Transplant 11:820-824, 1996
29. Seligman PA, Schleicher RB: Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem 45:898-901, 1999
30. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K: Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 15:1827-1834, 2000
31. Seifert A, von Herrath D, Schaefer K: Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q J Med 65:1015-1024, 1987
32. Tielemans CL, Lenclud CM, Wens R, Collart FE, Dratwa M: Critical role of Iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. Nephrol Dial Transplant 4:883-887, 1989
33. Hoen B, Kessler M, Hestin D, Mayeux D: Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. Nephrol Dial Transplant 10:377-381, 1995
34. Canziani ME, Yumiya ST, Rangel EB, Manfredi SR, Neto MC, Draibe SA: Risk of bacterial infection in patients under intravenous iron therapy: dose versus length of treatment. Artif Organs 25:866-869, 2001
35. Brewster UC, Coca SG, Reilly RF, Perazella MA: Effect of intravenous iron on haemodialysis catheter microbial colonization and blood-borne infection. Nephrology (Carlton) 10:124-128, 2005
36. Hoen B, Paul-Dauphin A, Hestin D, Kessler M: Epibacdial: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 9:869-876, 1998
37. Collins A, Ebben J, Ma J, Xia H: IV Iron dosing patterns and mortality [abstract]. J Am Soc Nephrol 9:205A, 1998
38. Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, Marcus S, Faich G: Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13:734-744, 2002
39. Harford A, Stidley C, Hunt C, Paine S, Pai A, Scavini S, Brown R, Zager P. Iron dose and survival in hemodialysis patients. J Am Soc Nephrol 14:266A, 2003
40. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G: Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15:1623-1632, 2004
41. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62:1524-1538, 2002
42. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C: Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 18:1272-1280, 2003
43. Biemond P, Swaak AJ, van Eijk HG, Koster JF: Superoxide dependent iron release from ferritin in inflammatory diseases. Free Radic Biol Med 4:185-198, 1988
44. Canavese C, Bergamo D, Ciccone G, Burdese M, Maddalena E, Barbieri S, Thea A, Fop F: Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients. Nephrol Dial Transplant 19:1564-1570, 2004
45. Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N: Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 40:1005-1012, 2002
46. Kiechl S, Aichner F, Gerstenbrand F, Egger G, Mair A, Rungger G, Spogler F, Jarosch E, Oberhollenzer F, Willeit J: Body iron stores and presence of carotid atherosclerosis. Results from the Bruneck study. Arterioscler Thromb 14:1625-1630, 1994
47. Sullivan JL: Iron and the sex difference in heart disease risk. Lancet 1:1293-1294, 1981
48. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R: High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 86:803-811, 1992
49. Ascherio A, Willett WC, Rimm EB, Giovannucci EL, Stampfer MJ: Dietary iron intake and risk of coronary disease among men. Circulation 89:969-974, 1994
50. Gartside PS, Glueck CJ: The important role of modifiable dietary and behavioral characteristics in the causation and prevention of coronary heart disease hospitalization and mortality: the prospective NHANES I follow-up study. J Am Coll Nutr 14:71-79, 1995
51. Corti MC, Guralnik JM, Salive ME, Ferrucci L, Pahor M, Wallace RB, Hennekens CH: Serum iron level, coronary artery disease, and all-cause mortality in older men and women. Am J Cardiol 79:120-127, 1997
52. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
53. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG: Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16:3070-3080, 2005
54. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106:2212-2217, 2002
55. Reis KA, Guz G, Ozdemir H, Erten Y, Atalay V, Bicik Z, Ozkurt ZN, Bali M, Sindel S: Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J 46:255-264, 2005
56. Bonkovsky HL, Banner BF, Rothman AL: Iron and chronic viral hepatitis. Hepatology 25:759-768, 1997
57. Caramelo C, Ortiz A, Aguilera B, Porres JC, Navas S, Marriott E, Alberola ML, Alamo C, Galera A, Garron MP, et al.: Liver disease patterns in hemodialysis patients with antibodies to hepatitis C virus. Am J Kidney Dis 22:822-828, 1993
58. Nascimento MM, Suliman ME, Bruchfeld A, Hayashi SY, Manfro RC, Qureshi AR, Pecoits-Filho R, Pachaly MA, Renner L, Stenvinkel P, Riella MC, Lindholm B: The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients. Nephrol Dial Transplant 19:3112-3116, 2004